Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
A Phase 1-2 Trial of MM-121 in Combination With Erlotinib in Three Groups of Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/23/2013
Clinical Research Facility
mi
from
Dallas, TX
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
A Phase 1-2 Trial of MM-121 in Combination With Erlotinib in Three Groups of Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/23/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Intellectual Impairment in Women With Breast Cancer
Assessment and Treatment of Cognitive Deficits in Breast Cancer
Status: Enrolling
Updated:  5/28/2013
Stanford University School of Medicine
mi
from
Stanford, CA
Intellectual Impairment in Women With Breast Cancer
Assessment and Treatment of Cognitive Deficits in Breast Cancer
Status: Enrolling
Updated: 5/28/2013
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
MRI/TRUS Fusion Guided Prostate Biopsy- An Improved Way to Detect and Quantify Prostate Cancer
MRI/TRUS Fusion Guided Prostate Biopsy- An Improved Way to Detect and Quantify Prostate Cancer. A Phase III Study
Status: Enrolling
Updated:  5/28/2013
Arthur Smith Institute for Urology
mi
from
New Hyde Park, NY
MRI/TRUS Fusion Guided Prostate Biopsy- An Improved Way to Detect and Quantify Prostate Cancer
MRI/TRUS Fusion Guided Prostate Biopsy- An Improved Way to Detect and Quantify Prostate Cancer. A Phase III Study
Status: Enrolling
Updated: 5/28/2013
Arthur Smith Institute for Urology
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Impact of Breast Magnetic Resonance Imaging (MRI) on Mastectomy Rates
Evaluation of Breast Magnetic Resonance Imaging (MRI) Impact on Mastectomy Rate at Summa Akron City Hospital
Status: Enrolling
Updated:  5/30/2013
Summa Akron City Hospital
mi
from
Akron, OH
Impact of Breast Magnetic Resonance Imaging (MRI) on Mastectomy Rates
Evaluation of Breast Magnetic Resonance Imaging (MRI) Impact on Mastectomy Rate at Summa Akron City Hospital
Status: Enrolling
Updated: 5/30/2013
Summa Akron City Hospital
mi
from
Akron, OH
Click here to add this to my saved trials
CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells
Phase I Trial Of Intrahepatic Infusion Of 2nd Generation Designer T Cells For Cea-Expressing Liver Metastases
Status: Enrolling
Updated:  6/3/2013
Roger Williams Medical Center
mi
from
Providence, RI
CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells
Phase I Trial Of Intrahepatic Infusion Of 2nd Generation Designer T Cells For Cea-Expressing Liver Metastases
Status: Enrolling
Updated: 6/3/2013
Roger Williams Medical Center
mi
from
Providence, RI
Click here to add this to my saved trials
Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer
Clinical Value of Pre-Surgery Positron Emission Mammography (PEM) in Patients With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  6/4/2013
Swedish Cancer Institute
mi
from
Seattle, WA
Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer
Clinical Value of Pre-Surgery Positron Emission Mammography (PEM) in Patients With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 6/4/2013
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer
Clinical Value of Pre-Surgery Positron Emission Mammography (PEM) in Patients With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  6/4/2013
Swedish Cancer Institute Cherry Hill Campus - Comprehensive Breast Center
mi
from
Seattle, WA
Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer
Clinical Value of Pre-Surgery Positron Emission Mammography (PEM) in Patients With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 6/4/2013
Swedish Cancer Institute Cherry Hill Campus - Comprehensive Breast Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Green Tea Anticancer Mechanisms in Smokers
Green Tea Anticancer Mechanisms in Smokers
Status: Enrolling
Updated:  6/4/2013
Ohio State University
mi
from
Columbus, OH
Green Tea Anticancer Mechanisms in Smokers
Green Tea Anticancer Mechanisms in Smokers
Status: Enrolling
Updated: 6/4/2013
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Green Tea Anticancer Mechanisms in Smokers
Green Tea Anticancer Mechanisms in Smokers
Status: Enrolling
Updated:  6/4/2013
Ohio State University
mi
from
Columbus, OH
Green Tea Anticancer Mechanisms in Smokers
Green Tea Anticancer Mechanisms in Smokers
Status: Enrolling
Updated: 6/4/2013
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Effective Communication for Preventing and Responding to Oncology Adverse Events
Effective Communication for Preventing and Responding to Oncology Adverse Events
Status: Enrolling
Updated:  6/4/2013
Kaiser Permanente Georgia
mi
from
Atlanta, GA
Effective Communication for Preventing and Responding to Oncology Adverse Events
Effective Communication for Preventing and Responding to Oncology Adverse Events
Status: Enrolling
Updated: 6/4/2013
Kaiser Permanente Georgia
mi
from
Atlanta, GA
Click here to add this to my saved trials
Effective Communication for Preventing and Responding to Oncology Adverse Events
Effective Communication for Preventing and Responding to Oncology Adverse Events
Status: Enrolling
Updated:  6/4/2013
Group Health
mi
from
Seattle, WA
Effective Communication for Preventing and Responding to Oncology Adverse Events
Effective Communication for Preventing and Responding to Oncology Adverse Events
Status: Enrolling
Updated: 6/4/2013
Group Health
mi
from
Seattle, WA
Click here to add this to my saved trials
Participation Restrictions in Breast Cancer Survivors
Participation Restrictions in Young-Middle Adult Rural Breast Cancer Survivors
Status: Enrolling
Updated:  6/6/2013
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Participation Restrictions in Breast Cancer Survivors
Participation Restrictions in Young-Middle Adult Rural Breast Cancer Survivors
Status: Enrolling
Updated: 6/6/2013
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy, in Combination With Carboplatin or in Combination With Docetaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  6/10/2013
Clinical Research Facility
mi
from
Chicago, IL
ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy, in Combination With Carboplatin or in Combination With Docetaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 6/10/2013
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy, in Combination With Carboplatin or in Combination With Docetaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  6/10/2013
Clinical Research Facility
mi
from
Houston, TX
ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy, in Combination With Carboplatin or in Combination With Docetaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 6/10/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Phase II Pilot Study With TMX 101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Status: Enrolling
Updated:  6/10/2013
BCG Oncology
mi
from
Phoenix, AZ
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Phase II Pilot Study With TMX 101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Status: Enrolling
Updated: 6/10/2013
BCG Oncology
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Phase II Pilot Study With TMX 101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Status: Enrolling
Updated:  6/10/2013
The Urology Center of Colorado
mi
from
Denver, CO
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Phase II Pilot Study With TMX 101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Status: Enrolling
Updated: 6/10/2013
The Urology Center of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Phase II Pilot Study With TMX 101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Status: Enrolling
Updated:  6/10/2013
Urologic Consultants of SE PA
mi
from
Bala Cynwyd, PA
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Phase II Pilot Study With TMX 101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Status: Enrolling
Updated: 6/10/2013
Urologic Consultants of SE PA
mi
from
Bala Cynwyd, PA
Click here to add this to my saved trials
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Phase II Pilot Study With TMX 101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Status: Enrolling
Updated:  6/10/2013
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Phase II Pilot Study With TMX 101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Status: Enrolling
Updated: 6/10/2013
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors
A Phase 1 Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors and Determination of Tumor Receptor Occupancy by U3-1287
Status: Enrolling
Updated:  6/11/2013
Washington University School of Medicine
mi
from
Saint Louis, MO
Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors
A Phase 1 Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors and Determination of Tumor Receptor Occupancy by U3-1287
Status: Enrolling
Updated: 6/11/2013
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Enhanced Self-Efficacy Training
Enhanced Self-Efficacy Training For Informal Cancer Caregivers
Status: Enrolling
Updated:  6/13/2013
Duke Univ Med Ctr
mi
from
Durham, NC
Enhanced Self-Efficacy Training
Enhanced Self-Efficacy Training For Informal Cancer Caregivers
Status: Enrolling
Updated: 6/13/2013
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/17/2013
TGen Clinical Research Services at Scottsdale Healthcare
mi
from
Scottsdale, AZ
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/17/2013
TGen Clinical Research Services at Scottsdale Healthcare
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/17/2013
New York Oncology Hematology PC
mi
from
Albany, NY
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/17/2013
New York Oncology Hematology PC
mi
from
Albany, NY
Click here to add this to my saved trials
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/17/2013
Institute for Translational Oncology Research
mi
from
Greenville, SC
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/17/2013
Institute for Translational Oncology Research
mi
from
Greenville, SC
Click here to add this to my saved trials
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/17/2013
Texas Oncology - Baylor, Charles A. Sammons Center
mi
from
Dallas, TX
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/17/2013
Texas Oncology - Baylor, Charles A. Sammons Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/17/2013
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/17/2013
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/17/2013
Tyler Cancer Center
mi
from
Tyler, TX
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/17/2013
Tyler Cancer Center
mi
from
Tyler, TX
Click here to add this to my saved trials
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/17/2013
Virginia Oncology Associates
mi
from
Norfolk, VA
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/17/2013
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/17/2013
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/17/2013
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/17/2013
Northwest Cancer Specialists
mi
from
Vancouver, WA
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/17/2013
Northwest Cancer Specialists
mi
from
Vancouver, WA
Click here to add this to my saved trials
BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)
H-25362: Effect of Botulinum Neurotoxin Type A Prostate Injections on Neurogenesis and Gene Profile Expression in Men With Localized Prostate Cancer and Lower Urinary Tract Symptoms/BPH (Protocol # 05-09-30-03)
Status: Enrolling
Updated:  6/17/2013
University of Texas- Houston Medical School
mi
from
Houston, TX
BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)
H-25362: Effect of Botulinum Neurotoxin Type A Prostate Injections on Neurogenesis and Gene Profile Expression in Men With Localized Prostate Cancer and Lower Urinary Tract Symptoms/BPH (Protocol # 05-09-30-03)
Status: Enrolling
Updated: 6/17/2013
University of Texas- Houston Medical School
mi
from
Houston, TX
Click here to add this to my saved trials
Direct Peritoneal Resuscitation Plus Conventional Resuscitation
A Comparison of Direct Peritoneal Resuscitation Plus Conventional Resuscitation Versus Conventional Resuscitation Alone in Patients Undergoing Hepatic Resection for Cancer
Status: Enrolling
Updated:  6/17/2013
Norton Hospital
mi
from
Louisville, KY
Direct Peritoneal Resuscitation Plus Conventional Resuscitation
A Comparison of Direct Peritoneal Resuscitation Plus Conventional Resuscitation Versus Conventional Resuscitation Alone in Patients Undergoing Hepatic Resection for Cancer
Status: Enrolling
Updated: 6/17/2013
Norton Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Direct Peritoneal Resuscitation Plus Conventional Resuscitation
A Comparison of Direct Peritoneal Resuscitation Plus Conventional Resuscitation Versus Conventional Resuscitation Alone in Patients Undergoing Hepatic Resection for Cancer
Status: Enrolling
Updated:  6/17/2013
University of Louisville Hospital
mi
from
Louisville, KY
Direct Peritoneal Resuscitation Plus Conventional Resuscitation
A Comparison of Direct Peritoneal Resuscitation Plus Conventional Resuscitation Versus Conventional Resuscitation Alone in Patients Undergoing Hepatic Resection for Cancer
Status: Enrolling
Updated: 6/17/2013
University of Louisville Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
Phase II and Coagulation Study of rhuMAb-VEGF With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  6/18/2013
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
Phase II and Coagulation Study of rhuMAb-VEGF With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 6/18/2013
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of VX15/2503 in Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  6/19/2013
Virginia G. Piper Cancer Center at Scottsdale Healthcare
mi
from
Scottsdale, AZ
Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of VX15/2503 in Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 6/19/2013
Virginia G. Piper Cancer Center at Scottsdale Healthcare
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of VX15/2503 in Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  6/19/2013
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of VX15/2503 in Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 6/19/2013
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling
Randomized Controlled Trial Examining the Return of Urinary Continence After Robot-assisted Radical Prostatectomy With or Without a Urethrovesical Sling
Status: Enrolling
Updated:  6/25/2013
Clarian North Medical Center
mi
from
Carmel, IN
Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling
Randomized Controlled Trial Examining the Return of Urinary Continence After Robot-assisted Radical Prostatectomy With or Without a Urethrovesical Sling
Status: Enrolling
Updated: 6/25/2013
Clarian North Medical Center
mi
from
Carmel, IN
Click here to add this to my saved trials
Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling
Randomized Controlled Trial Examining the Return of Urinary Continence After Robot-assisted Radical Prostatectomy With or Without a Urethrovesical Sling
Status: Enrolling
Updated:  6/25/2013
Indiana University School of Medicine
mi
from
Indianapolis, IN
Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling
Randomized Controlled Trial Examining the Return of Urinary Continence After Robot-assisted Radical Prostatectomy With or Without a Urethrovesical Sling
Status: Enrolling
Updated: 6/25/2013
Indiana University School of Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling
Randomized Controlled Trial Examining the Return of Urinary Continence After Robot-assisted Radical Prostatectomy With or Without a Urethrovesical Sling
Status: Enrolling
Updated:  6/25/2013
Urology San Antonio Research
mi
from
San Antonio, TX
Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling
Randomized Controlled Trial Examining the Return of Urinary Continence After Robot-assisted Radical Prostatectomy With or Without a Urethrovesical Sling
Status: Enrolling
Updated: 6/25/2013
Urology San Antonio Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
Alhambra, CA
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
Alhambra, CA
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
San Francisco, CA
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
Spring Valley, CA
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
Spring Valley, CA
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
Coral Gables, FL
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
Miami, FL
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
South Miami, FL
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
South Miami, FL
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
Orlando, FL
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
Chicago, IL
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
Indianapolis, IN
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
Marrero, LA
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
Marrero, LA
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
Elkridge, MD
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
Elkridge, MD
Click here to add this to my saved trials
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated:  6/26/2013
Clinical Research Facility
mi
from
Kansas City, MO
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Status: Enrolling
Updated: 6/26/2013
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials